Citi Starts Pliant Therapeutics (PLRX) at Buy
Tweet Send to a Friend
Citi analyst Mohit Bansal initiates coverage on Pliant Therapeutics (NASDAQ: PLRX) with a Buy rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE